Share Buybacks

As outlined in the announcement on 29 February 2024, the intention was that Haleon plc would execute the share buybacks on the open market or off-market if the opportunity arises. 

On 21 March 2024, Haleon plc announced that it had participated in Pfizer Inc’s secondary global offering and completed an off-market purchase of 102,272,727 ordinary shares from Pfizer Inc. at an aggregate price of approximately £315 million. All of the repurchased ordinary shares were cancelled. Further details are available here.

On 1 August 2024, Haleon plc announced the commencement of an on-market share buyback programme up to an aggregate consideration of £185 million. The purpose of the Buyback Programme is to reduce share capital and therefore ordinary shares purchased under the buyback will be cancelled. The announcement is available here .

The buyback programme will take place in accordance with Haleon plc’s current buyback authority granted by shareholders at the Company’s 2024 Annual General Meeting. The maximum number shares that may be repurchased under that authority is 913,000,000. 

A breakdown of the daily transaction details can be found here and is updated weekly during the buyback programme if shares have been repurchased within the prior week.